Background: Thyroid cancer: The incidence of thyroid cancer has doubled over the last two decades. Although most patients with thyroid cancer of follicular cell origin have an excellent prognosis, 10% - 15% will have refractory disease to conventional therapy (resection combined with radioiodine ablation and thyroid hormone for TSH suppression). Chemotherapy and external beam radiation are ineffective in patients with metastatic disease. The overall 10 year survival of patients with metastatic thyroid cancer of follicular cell origin is approximately 40-50%. Anaplastic thyroid cancer is one of the most lethal solid malignancies with no currently available effective systemic therapy. Adrenocortical carcinoma: Approximately two-thirds of patients who present with adrenocortical carcinoma have locoregional disease and metastasis. Unfortunately, despite combined multimodality therapy, the overall prognosis of patients with adrenocortical carcinoma remains dismal, with a 5-year survival of less than 35%. Summary: We have made progress towards identifying molecular targets and novel agents for thyroid and adrenocortical carcinoma therapy. From our pangenomic studies of endocrine cancers (thyroid and adrenal), we have identified altered genes/pathways which are druggable targets such as dysregulated methylation of tumor suppressor genes and histone deacetylase expression, and elevated survivin expression in poorly differentiated and anaplastic thyroid cancer. By integrating this data with our quantitative high throughput drug library screening of over 3,000 compounds, which demonstrated enriched activity of compounds targeting dysregulated genes/pathways in thyroid cancer cells. We have completed preclinical studies of 5 agents which showed excellent activity inhibiting growth and metastases of thyroid cancer cells (4 agents) and adrenocortical carcinoma cells (1 agent). Moreover, we have identified biomarkers of response to treatment validated in our preclinical studies that are present human thyroid and adrenocortical carcinoma tissue samples. We have completed combination compound matrix drug screening of 28 active compounds and have identified 4 synergistic agents which we are evaluating in our preclinical models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011286-06
Application #
9153844
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
El Lakis, Mustapha; Nockel, Pavel; Gaitanidis, Apostolos et al. (2018) Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. J Am Coll Surg 226:933-938
Nilubol, Naris; Yuan, ZiQiang; Paciotti, Giulio F et al. (2018) Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. J Natl Cancer Inst :
Zhang, Ling; Lu, Le; Summers, Ronald M et al. (2018) Convolutional Invasion and Expansion Networks for Tumor Growth Prediction. IEEE Trans Med Imaging 37:638-648
Sadowski, Samira Mercedes; Pusztaszeri, Marc; Brulhart-Meynet, Marie-Claude et al. (2018) Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism. J Clin Endocrinol Metab 103:2189-2198
Luo, Hongxiu; Tobey, Andrew; Auh, Sungyoung et al. (2018) The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. Clin Endocrinol (Oxf) 89:481-488
Kebebew, Electron (2018) Ethnic specific differences in endocrine neoplasms: The role of susceptibility genes. Am J Surg 215:1060-1061
Kebebew, Electron (2018) Thyroid Cancer: Is It All in the Genes? J Natl Cancer Inst 110:327-328
Tirosh, Amit; El Lakis, Mustapha; Green, Patience et al. (2018) In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. J Clin Endocrinol Metab 103:1631-1638
El Lakis, Mustapha; Nockel, Pavel; Guan, Bin et al. (2018) Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery 163:31-34
Nockel, Pavel; El Lakis, Mustapha; Gaitanidis, Apostolos et al. (2018) Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery 163:191-196

Showing the most recent 10 out of 29 publications